WAM
PCRX icon

Wealthspire Advisors (Maryland)’s Pacira BioSciences PCRX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5
Closed – – 1560
2019
Q1 		$0 Hold
5
– – ﹤0.01% 2558
2018
Q4 		$0 Hold
5
– – ﹤0.01% 2533
2018
Q3 		$0 Hold
5
– – ﹤0.01% 2471
2018
Q2 		$0 Hold
5
– – ﹤0.01% 2538
2018
Q1 		$0 Hold
5
– – ﹤0.01% 2604
2017
Q4 		$0 Hold
5
– – ﹤0.01% 2522
2017
Q3 		$0 Hold
5
– – ﹤0.01% 2404
2017
Q2 		$0 Hold
5
– – ﹤0.01% 2251
2017
Q1 		$0 Hold
5
– – ﹤0.01% 1991
2016
Q4 		$0 Buy
+5
New +$167 ﹤0.01% 1817

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s PCRX Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 5 shares.

Wealthspire Advisors (Maryland) first reported a position in PCRX in Q4 2016 and held it in 10 quarters. The position peaked at $0 in Q1 2019. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 5 Pacira BioSciences shares in Q2 2019.
  • Wealthspire Advisors (Maryland) first reported a position in Pacira BioSciences in Q4 2016 and held it in 10 quarters.
  • Wealthspire Advisors (Maryland)'s Pacira BioSciences position peaked at $0 in Q1 2019.
  • 218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.